Chemical Structure (Pemfexy Figure 01)
Pemfexy Injection
Product Images NDC 71390-250
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemfexy (NDC 71390-250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Acacia Pharma, Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pemfexy Figure 02)
Figure 2 (Pemfexy Figure 03)
This is a survival probability chart showing patients at risk over different time periods for the treatments Pemetrexed + Cisplatin and Gemcitabine + Cisplatin. The chart also displays survival time in months for the patients.*
Figure 3 (Pemfexy Figure 04)
This text appears to be a chart showing the survival time in months for patients receiving different treatments (Pemetrexed + Cisplatin and Gemcitabine + Cisplatin). The chart also includes the number of patients at risk at specific time points. It is not readable and does not provide a complete description.*
Figure 4 (Pemfexy Figure 05)
Survival Probability chart showing two different treatments: Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The chart displays the number of patients at risk for each treatment over different time periods in months, with corresponding survival times and probabilities.*
Figure 5 (Pemfexy Figure 06)
This text presents data on survival time in months for patients taking two different treatments: Pemevexed and Placebo. The number of patients at risk is detailed for each duration of treatment. The data can be used to analyze the probability of survival over time for both groups of patients.*
Figure 6 (Pemfexy Figure 07)
This data table represents the survival probability of patients using Pemetrexed compared to Placebo over a period of 39 months. The number of patients at risk for each treatment is listed at various time points, showing a trend in survival time.*
Figure 7 (Pemfexy Figure 08)
This data appears to be showing survival probabilities for patients treated with Pemetrexed and Placebo over different periods of time, measured in months. The table also includes the number of patients at risk at different time points.*
Figure 8 (Pemfexy Figure 09)
This text provides information on the survival time in months for patients treated with Pemetrexed compared to Placebo. It shows the number of patients at risk for each treatment group at different time points.*
Figure 9 (Pemfexy Figure 10)
This is a clinical study report showing the survival probability and survival time (in months) of patients under treatment with pemetrexed + Cisplatin. The report includes the number of patients at risk for both treatments at different time points.*
25mg/ml Vial Label (Pemfexy Figure 11)
Description: This is information regarding a multi-dose vial of PEMFEXY (Pemetrexed Injection) containing 500 mg/20 mL (25 mg/mL). It is an intravenous fusion and a cytotoxic agent. The product is sterile and is used for various types of cancer treatment. The label includes dosage instructions and the NDC number. It is for prescription use only and should be handled and administered as directed.*
25mg/ml Vial Label (Pemfexy Figure 12)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
